S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
Positive News Sentiment  
NASDAQ:TRVI

Trevi Therapeutics - TRVI Stock Forecast, Price & News

$2.46
+0.13 (+5.58%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.30
▼
$2.61
50-Day Range
$1.74
▼
$2.82
52-Week Range
$0.46
▼
$4.68
Volume
45,202 shs
Average Volume
42,472 shs
Market Capitalization
$147.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

Trevi Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
235.4% Upside
$8.25 Price Target
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.90mentions of Trevi Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.54) to ($0.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

207th out of 1,055 stocks

Pharmaceutical Preparations Industry

96th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

TRVI stock logo

About Trevi Therapeutics (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

January 25, 2023 | finance.yahoo.com
Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast
January 5, 2023 | finance.yahoo.com
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 26, 2022 | finance.yahoo.com
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) stock price dropped 13% last week; private equity firms would not be happy
December 23, 2022 | seekingalpha.com
TRVI Trevi Therapeutics, Inc.
December 19, 2022 | finance.yahoo.com
Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference
November 14, 2022 | finance.yahoo.com
Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer
November 13, 2022 | seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 10, 2022 | finance.yahoo.com
Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022 | benzinga.com
Earnings Outlook For Trevi Therapeutics, Inc. - Common Stock
November 8, 2022 | finance.yahoo.com
Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference
November 4, 2022 | finance.yahoo.com
Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022
October 27, 2022 | finance.yahoo.com
Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting
September 23, 2022 | au.investing.com
After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on...
September 23, 2022 | finance.yahoo.com
/C O R R E C T I O N -- Trevi Therapeutics, Inc./
September 23, 2022 | finance.yahoo.com
Trevi Therapeutics Announces Proposed Public Offering
September 19, 2022 | finance.yahoo.com
Trevi Therapeutics Shares Jump After Complete Data From Chronic Cough Trial
September 19, 2022 | markets.businessinsider.com
Trevi Reports Positive Results From Full Set Of Subjects From CANAL Trial Of Haduvio
September 19, 2022 | finance.yahoo.com
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
September 14, 2022 | finance.yahoo.com
Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?
September 11, 2022 | seekingalpha.com
Trevi Therapeutics: Moving Forward
August 30, 2022 | finance.yahoo.com
Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022
August 16, 2022 | nasdaq.com
What Type Of Shareholders Own The Most Number of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares?
August 11, 2022 | finance.yahoo.com
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
August 8, 2022 | msn.com
Gloria Trevi On the Highs and Lows of Her 40-Year Career — And What Has Remained Consistent In Her Music
August 4, 2022 | finance.yahoo.com
Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Company Calendar

Last Earnings
11/10/2022
Today
1/28/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVI
CUSIP
N/A
CIK
1563880
Web
www.trevitherapeutics.com
Phone
(203) 304-2499
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+235.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,940,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-65.00%
Return on Assets
-46.18%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
8.70
Quick Ratio
8.70

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.66 per share
Price / Book
3.73

Miscellaneous

Outstanding Shares
59,920,000
Free Float
36,241,000
Market Cap
$147.40 million
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Jennifer L. Good
    President, Chief Executive Officer & Director
  • Lisa Delfini
    Chief Financial Officer
  • Thomas R. Sciascia
    Chief Science Officer
  • Danine Summers
    Vice President-Medical Affairs
  • David J. Clark
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TRVI Stock - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings or view top-rated stocks.

What is Trevi Therapeutics' stock price forecast for 2023?

4 analysts have issued 1 year target prices for Trevi Therapeutics' shares. Their TRVI share price forecasts range from $6.00 to $10.00. On average, they predict the company's stock price to reach $8.25 in the next year. This suggests a possible upside of 235.4% from the stock's current price.
View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2023?

Trevi Therapeutics' stock was trading at $1.93 at the beginning of the year. Since then, TRVI stock has increased by 27.5% and is now trading at $2.46.
View the best growth stocks for 2023 here.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our TRVI earnings forecast.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its quarterly earnings data on Thursday, November, 10th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $2.46.

How much money does Trevi Therapeutics make?

Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $147.41 million. The company earns $-33,940,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com.

This page (NASDAQ:TRVI) was last updated on 1/28/2023 by MarketBeat.com Staff